<DOC>
	<DOCNO>NCT01398241</DOCNO>
	<brief_summary>This investigator-blind , subject-blind , randomize , placebo-controlled study evaluate safety , pharmacokinetics pharmacodynamics multiple ascend dos RO5267683 healthy volunteer . Subjects randomize receive either RO5267683 placebo orally daily 28 day . Follow-up 10 week last dose .</brief_summary>
	<brief_title>A Study RO5267683 Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy male female subject , 18 45 year age , Body mass index ( BMI ) 18 30 kg/m2 inclusive , minimum weight 50 kg screen Female subject must surgically sterile postmenopausal Male subject must use barrier method contraception duration study 90 day last dose History evidence clinically significant disease disorder Administration investigational drug device within 3 month prior dose Day 1 Positive hepatitis B , hepatitis C HIV screen Subjects hormone replacement therapy receive stable dose least 2 month prior start dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>